)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nanexa
Nanexa (NANEXA) investor relations material
Nanexa Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary27 Aug, 2026
Executive summary
Focused on commercial expansion and increased visibility of PharmaShell technology through international forums and industry publications.
Advanced licensing negotiations for PharmaShell in obesity and type 2 diabetes markets, with parallel development of long-acting semaglutide depot.
Ongoing collaborations with Moderna and another major pharmaceutical company, with promising evaluation results and potential for expanded partnerships.
Strengthened patent portfolio with new grants and applications, extending protection into the mid-2040s.
Financial position remains strong, with cash runway until Q2 2027 and further strengthening expected from licensing agreements.
Financial highlights
Q2 2026 turnover: SEK 1,654 thousand (down from SEK 2,705 thousand year-over-year).
Operating profit (EBIT) for Q2: SEK -13,882 thousand (vs. SEK -5,237 thousand year-over-year).
Profit after tax for Q2: SEK -14,032 thousand (vs. SEK -5,899 thousand year-over-year).
Cash and cash equivalents at period end: SEK 52,557 thousand (up from SEK 40,263 thousand year-over-year).
Earnings per share Q2: SEK -0.07 (vs. SEK -0.04 year-over-year).
Outlook and guidance
Cash position expected to finance operations until Q2 2027.
Additional financing will be considered only if terms reflect full company value.
Active pursuit of revenue from licensing and collaboration agreements to ensure long-term financing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nanexa
- NEX-22 Phase I completed; losses narrowed, but further financing is required.NANEXA
Q3 2024 - Strong R&D advances and improved funding position support future growth despite Q1 losses.NANEXAQ1 2026
- Moderna deal and NEX-22 focus drive revenue surge and improved outlook for 2026.NANEXAQ4 2025
- Major partnership extended, patent granted, and funding secured amid revenue decline.NANEXAQ3 2025
- NEX-22 Phase I results support once-monthly dosing; financials show extended runway to Q1 2026.NANEXAQ2 2025
- NEX-22 clinical trial launched; losses narrowed, but new funding required within a year.NANEXAQ2 2024
- NEX-22 clinical progress and new financing position Nanexa for growth despite Q1 losses.NANEXAQ1 2025
- Positive NEX-22 clinical results and new financing position Nanexa for 2025 growth.NANEXAQ4 2024
Next Nanexa earnings date
Q3 20265 Nov, 2026
Nanexa
Next Nanexa earnings date
Q3 20265 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Nanexa AB focuses on developing nanoparticle technology for drug delivery. The company utilizes their proprietary NxCore platform to transform drugs from conventional to nanomedicines. Their lead product candidate is Nanoxel, a nanomedicine that targets oral mucositis, a common and exceptionally debilitating side effect in cancer patients receiving chemotherapy and radiation therapies; and angina pectoris and heart failure caused by atherosclerosis, a build-up of plaque in the blood vessels. The company intends to transform new products into nanomedicines or develop completely new nanomedicines.